Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 9/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001198 | 1.00 | DGAT1 (0.49) | DGAT1FFAR1LPLLIPGUSP30 | |
| Hydrochloric Acid SCHEMBL14991383 | 0.98 | DGAT1 (0.48) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL19051887 | 0.89 | DGAT1 (0.46) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL16272832 | 0.87 | DGAT1 (0.48) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL15001186 | 0.87 | DGAT1 (0.48) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL15001205 | 0.86 | DGAT1 (0.44) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL29744208 | 0.84 | DGAT1 (0.46) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL20299135 | 0.84 | DGAT1 (0.46) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL24456709 | 0.83 | DGAT1 (0.49) | DGAT1FFAR1LPLLIPGUSP30 | |
| SCHEMBL29504614 | 0.82 | LPL (0.45) | DGAT1FFAR1LPLLIPGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | DGAT1 2843/4885FFAR1 1461/4885LPL 2418/4885 |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | DGAT1 4418/4885FFAR1 4491/4885LPL 1774/4885 |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | ZAP70, FLT3, LCK | DGAT1 4737/4885FFAR1 1368/4885LPL 3967/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | DGAT1 1164/4885FFAR1 1502/4885LPL 87/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | DGAT1 1428/4885FFAR1 65/4885LPL 642/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885FFAR1 4181/4885LPL 4686/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | DGAT1 2520/4885FFAR1 1699/4885LPL 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.